Bioengineering: α1-Proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor

Maurizio Luisetti, James Travis

Research output: Contribution to journalArticle

Abstract

α1-Proteinase inhibitor (α1-PI) augmentation therapy has been licensed for treatment of α1-PI-deficient individuals with pulmonary emphysema. The currently available product is purified from pooled human plasma. To obtain larger amounts of protein free from possible unknown plasma contaminants, human α1-PI has been produced by recombinant DNA. Since wild- type α1-PI is susceptible to oxidative impairment, several α1-PI variants in which the active site oxidation-sensitive residue is replaced by inert residues have been constructed. This article is aimed at reviewing the history biological efficacy, advantages, disadvantages, and concerns linked to α1-PI recombinant DNA and site-specific mutagenesis technology.

Original languageEnglish
JournalChest
Volume110
Issue number6 SUPPL.
Publication statusPublished - 1996

Fingerprint

Bioengineering
Site-Directed Mutagenesis
Peptide Hydrolases
Recombinant DNA
Pulmonary Emphysema
Catalytic Domain
History
Technology
Proteins

Keywords

  • α-PI deficiency
  • neutrophil elastase
  • oxidants
  • pulmonary emphysema
  • recombinant DNA

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Bioengineering : α1-Proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor. / Luisetti, Maurizio; Travis, James.

In: Chest, Vol. 110, No. 6 SUPPL., 1996.

Research output: Contribution to journalArticle

@article{0420d93dacfc43ae8110b8fec2997e0f,
title = "Bioengineering: α1-Proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor",
abstract = "α1-Proteinase inhibitor (α1-PI) augmentation therapy has been licensed for treatment of α1-PI-deficient individuals with pulmonary emphysema. The currently available product is purified from pooled human plasma. To obtain larger amounts of protein free from possible unknown plasma contaminants, human α1-PI has been produced by recombinant DNA. Since wild- type α1-PI is susceptible to oxidative impairment, several α1-PI variants in which the active site oxidation-sensitive residue is replaced by inert residues have been constructed. This article is aimed at reviewing the history biological efficacy, advantages, disadvantages, and concerns linked to α1-PI recombinant DNA and site-specific mutagenesis technology.",
keywords = "α-PI deficiency, neutrophil elastase, oxidants, pulmonary emphysema, recombinant DNA",
author = "Maurizio Luisetti and James Travis",
year = "1996",
language = "English",
volume = "110",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Bioengineering

T2 - α1-Proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor

AU - Luisetti, Maurizio

AU - Travis, James

PY - 1996

Y1 - 1996

N2 - α1-Proteinase inhibitor (α1-PI) augmentation therapy has been licensed for treatment of α1-PI-deficient individuals with pulmonary emphysema. The currently available product is purified from pooled human plasma. To obtain larger amounts of protein free from possible unknown plasma contaminants, human α1-PI has been produced by recombinant DNA. Since wild- type α1-PI is susceptible to oxidative impairment, several α1-PI variants in which the active site oxidation-sensitive residue is replaced by inert residues have been constructed. This article is aimed at reviewing the history biological efficacy, advantages, disadvantages, and concerns linked to α1-PI recombinant DNA and site-specific mutagenesis technology.

AB - α1-Proteinase inhibitor (α1-PI) augmentation therapy has been licensed for treatment of α1-PI-deficient individuals with pulmonary emphysema. The currently available product is purified from pooled human plasma. To obtain larger amounts of protein free from possible unknown plasma contaminants, human α1-PI has been produced by recombinant DNA. Since wild- type α1-PI is susceptible to oxidative impairment, several α1-PI variants in which the active site oxidation-sensitive residue is replaced by inert residues have been constructed. This article is aimed at reviewing the history biological efficacy, advantages, disadvantages, and concerns linked to α1-PI recombinant DNA and site-specific mutagenesis technology.

KW - α-PI deficiency

KW - neutrophil elastase

KW - oxidants

KW - pulmonary emphysema

KW - recombinant DNA

UR - http://www.scopus.com/inward/record.url?scp=0030476672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030476672&partnerID=8YFLogxK

M3 - Article

C2 - 8989165

AN - SCOPUS:0030476672

VL - 110

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6 SUPPL.

ER -